Table 3:
Prevalence of viral loads at specific thresholds by previous viral load result
| ≤50 copies per mL | 51–199 copies per mL | 200–999 copies per mL | ≥1000 copies per mL | |
|---|---|---|---|---|
| Range of most recent viral load result (non-dolutegravir-based ART) | ||||
| ≤50 copies per mL (n=82 091) | 69 144 (84·2%) | 5997 (7·3%) | 2835 (3·5%) | 4115 (5·0%) |
| 51–999 copies per mL (n=19 618) | 12 267 (62·5%) | 3588 (18·3%) | 1705 (8·7%) | 2058 (10·5%) |
| 51–199 copies per mL (n=12 687) | 8131 (64·1%) | 2628 (20·7%) | 813 (6·4%) | 1115 (8·8%) |
| 200–399 copies per mL (n=3599) | 2227 (61·9%) | 508 (14·1%) | 465 (12·9%) | 399 (11·1%) |
| 400–999 copies per mL (n=3332) | 1909 (57·3%) | 452 (13·6%) | 427 (12·8%) | 544 (16·3%) |
| ≥1000 copies per mL (n=3381) | 1675 (49·5%) | 401 (11·9%) | 302 (8·9%) | 1003 (29·7%) |
| Total (n=105 090) | 83 086 (79·1%) | 9986 (9·5%) | 4842 (4·6%) | 7176 (6·8%) |
| Range of most recent viral load result (dolutegravir-based ART) | ||||
| ≤50 copies per mL (n=237 621) | 203 295 (85·6%) | 16 875 (7·1%) | 7316 (3·1%) | 10 135 (4·3%) |
| 51–999 copies per mL (n=47 699) | 32 879 (68·9%) | 7820 (16·4%) | 3335 (7·0%) | 3665 (7·7%) |
| 51–199 copies per mL (n=32 093) | 22 266 (69·4%) | 5794 (18·1%) | 1826 (5·7%) | 2207 (6·9%) |
| 200–399 copies per mL (n=8066) | 5497 (68·2%) | 1098 (13·6%) | 766 (9·5%) | 705 (8·7%) |
| 400–999 copies per mL (n=7540) | 5116 (67·9%) | 928 (12·3%) | 743 (9·9%) | 753 (10·0%) |
| ≥1000 copies per mL (n=10 174) | 6378 (62·7%) | 1294 (12·7%) | 736 (7·2%) | 1766 (17·4%) |
| Total (n=295 494) | 242 552 (82·1%) | 25 989 (8·8%) | 11 387 (3·9%) | 15 566 (5·3%) |
| Total, all regimens (n=400 584) | 325 638 (81·3%) | 35 975 (9·0%) | 16 229 (4·1%) | 22 742 (5·7%) |
Data are n (%). ART=antiretroviral therapy.